FDA to alter biosimilar ‘suffix’ policy


FDA to alter biosimilar ‘suffix’ policy

jarretera / Shutterstock.com

The US Food and Drug Administration (FDA) yesterday announced draft revisions to its policy on the naming of biosimilars, in an attempt to appease critics who say that renaming previously-licensed products is too expensive.

US Food and Drug Administration, Scott Gottlieb, biosimilars, naming convention, names, suffix, pharmacovigilance, competition, transition